Accès ouvert

Lumefantrine-neusilin® based amorphous multicomponent solid dispersion: In vivo and in vitro characterization

Article scientifique 2025 Anglais

Résumé

Purpose: To develop Neusilin-based amorphous multi-component solid dispersions (NAM-SDs) to improve poor aqueous solubility, low bioavailability and absorption of lumefantrine and enhance the antiplasmodial activity.Methods: Solvent evaporation technique was adopted to produce second-generation SDs (N1 - N3); third-generation SDs (N4 - N6 and N10 - N12); and multi-component SDs, NAM-SDs, (N7 - N9 and N13 - N18). In vitro drug release, in vivo anti-plasmodial activity, differential scanning calorimetry (DSC), and wide-angle x-ray diffraction (WAXD) were carried out on the SDs.Results: The highest drug release (80 %) was observed in multi-component SDs (NAM-SDs, formulation N17 containing Kollidon® VA 64). A significant antiplasmodial activity (p < 0.05) was observed in mice that received NAM-SDs. The DSC and WAXD studies showed that the formulations solubilized and exhibited an amorphous state.Conclusion: Multi-component amorphous-based lumefantrine SDs (NAM-SDs) may serve as a potential alternative carrier system for oral lumefantrine delivery.

Citer ce document

Ugwu, C., Onyishi, I., Onunkwo, G., Obitte, B., Diovu, E., Momoh, M. (2025). Lumefantrine-neusilin® based amorphous multicomponent solid dispersion: In vivo and in vitro characterization. https://doi.org/10.4314/tjpr.v23i12.2

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Auteur(s)

Calister E. Ugwu Ikechukwu V. Onyishi Godswill C. Onunkwo Bridget Obitte Edith Obioma Diovu Mumuni Audu Momoh

Statistiques

Consultations : 1

Téléchargements : 0